TOMI Taps Total Clean Air as European Partner for SteraMist iHP Expansion
Event summary
- TOMI names Total Clean Air as its preferred European partner for SteraMist iHP decontamination technology, effective March 3, 2026.
- Total Clean Air will handle sales, service, and technical support across the UK and EU for SteraMist iHP.
- The UK infection control market is projected to exceed $6 billion USD by 2031, with a 14% CAGR in sterility testing through 2035.
- Total Clean Air will maintain consignment stock of SteraMist iHP equipment and provide validation support in Europe.
The big picture
TOMI's partnership with Total Clean Air aligns with the growing demand for high-level decontamination in regulated European markets. The collaboration addresses increasing MHRA and EU GMP Annex 1 requirements, positioning SteraMist iHP as a key solution for aseptic processing and contamination control. The UK's projected $6 billion infection control market and 14% CAGR in sterility testing underscore the strategic timing of this expansion.
What we're watching
- Regulatory Tailwinds
- Whether TOMI can leverage EU GMP Annex 1 compliance requirements to accelerate SteraMist iHP adoption.
- Execution Risk
- The pace at which Total Clean Air can integrate and scale SteraMist iHP support across Europe.
- Market Penetration
- How effectively TOMI and Total Clean Air can convert interest from Pharma, Biotech, and medical device manufacturers into revenue.
Related topics